(-)-N-[11C]propyl-norapomorphine: A positron-labeled dopamine agonist for PET imaging of D2 receptors

Nuclear Medicine and Biology

Volumn 27, Issue 6, 2000, Pages 533-539

  Hwang, Dah Ren ^a,b   Kegeles, Lawrence S ^a   Laruelle, Marc ^a  

^a New York State Psychiatric Institute ^*  (United States)

^b NEW YORK STATE PSYCHIATRIC INSTITUTE   (United States)

Author keywords

( ) NPA; Agonist; Carbon 11; D2 receptor; PET

Indexed keywords

CARBON 14; DOPAMINE 2 RECEPTOR STIMULATING AGENT; NORAPOMORPHINE; APOMORPHINE; CARBON; DOPAMINE 2 RECEPTOR; DOPAMINE RECEPTOR BLOCKING AGENT; DOPAMINE RECEPTOR STIMULATING AGENT; DRUG DERIVATIVE; HALOPERIDOL; N-N-PROPYLNORAPOMORPHINE; ORGANOMETALLIC COMPOUND; PROPANOYL CHLORIDE; PROPIONIC ACID DERIVATIVE; PROPYLNORAPOMORPHINE; TRACER;

ANIMAL EXPERIMENT; ARTICLE; BABOON; DRUG RECEPTOR BINDING; ISOTOPE LABELING; MALE; NEUROTRANSMISSION; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; RAT; RECEPTOR AFFINITY; ANIMAL; BINDING COMPETITION; CEREBELLUM; CHEMISTRY; COMPUTER ASSISTED EMISSION TOMOGRAPHY; CORPUS STRIATUM; DRUG EFFECT; METABOLISM; METHODOLOGY; NUCLEAR MAGNETIC RESONANCE IMAGING; PAPIO; SCINTISCANNING; SENSITIVITY AND SPECIFICITY; SPRAGUE DAWLEY RAT; SYNTHESIS; TISSUE DISTRIBUTION;

ANIMALS; APOMORPHINE; BINDING, COMPETITIVE; CARBON RADIOISOTOPES; CEREBELLUM; CORPUS STRIATUM; DOPAMINE AGONISTS; DOPAMINE ANTAGONISTS; HALOPERIDOL; MAGNETIC RESONANCE IMAGING; MALE; ORGANOMETALLIC COMPOUNDS; PAPIO; PROPIONATES; RADIOACTIVE TRACERS; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, DOPAMINE D2; SENSITIVITY AND SPECIFICITY; TISSUE DISTRIBUTION; TOMOGRAPHY, EMISSION-COMPUTED;

EID: 0033623451     PISSN: 09698051     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0969-8051(00)00144-X     Document Type: Article

References (32)

1. Increased striatal dopamine transmission in schizophrenia: Confirmation in a second cohort
2. N-n-propyl-norapomorphine: An extremely potent stimulant of dopamine autoreceptors
3. Schizophrenia is associated with elevated amphetamine-induced synaptic dopamine concentrations: Evidence from a novel positron emission tomography method
4. Relative selectivity of 6,7-dihydroxy-2-dimethylaminotetralin, N-n-propyl-3-(3-hydroxyphenyl)piperidine, N-n-propylnorapomorphine and pergolide as agonists at striatal dopamine autoreceptors and postsynaptic dopamine receptors
5. 11C-raclopride is altered by drugs that modify synaptic dopamine levels
6. Agonist action at D2(long) dopamine receptors: Ligand binding and functional assays
7. Complete conversion of brain D2 dopamine receptors from the high- to the low-affinity state for dopamine agonists, using sodium ions and guanine nucleotide
8. Effects of discriminant and non-discriminant dopamine antagonists on in vivo accumulation of 3H-N-propyl-norapomorphine in mouse striatum and tuberculum olfactorium
9. Preparation of two potent and selective dopamine D-2 receptor agonists: (R)-[propyl-11C]-2-OH-NPA and (R)-[methyl-11C]-2-OCH3-NPA
10. An improved one-pot procedure for the preparation of [11C-carbonyl]-WAY100635
11. Synthesis of positron-labeled dopamine agonist, [C-11]pramipexole and its derivatives
12. 2 receptor in non-human primates
13. 3H]N-propylnorapomorphine in the mouse brain. Evidence for labelling of central dopamine receptors
14. Single photon emission computerized tomography imaging of amphetamine-induced dopamine release in drug free schizophrenic subjects
15. Microdialysis and SPECT measurements of amphetamine-induced dopamine release in nonhuman primates
16. Preparation of some NCA [1-11C]acid chlorides as labelling agents
17. Efficacy and potency comparisons among aporphine enantiomers: Effects on dopamine neurons in substantia nigra of rat
18. Comparison of the dopaminergic effects of apomorphine and (-)-N-n-propylnorapomorphine
19. Solid-phase reversible trap for [11C]carbon dioxide using carbon molecular sieves
20. Evaluation of dopamine D-2 receptor agonists. 11C-ZYY-339 and 11CPPHT as potential in vivo radiotracers
21. Aporphines. 8. Total synthesis and pharmacological evaluation of (plus or minus)-apomorphine, (plus or minus)-apocodeine, (plus or minus)-N-n- propylnorapomorphine, and (plus or minus)-N-n-propylnorapocodeine
22. Pharmacological characterization of dopamine-stimulated [35S]-guanosine 5'(gamma-thiotriphosphate) ([35S]GTPgammaS) binding in rat striatal membranes
23. 3H](-)-N-n-propylnorapomorphine in the mouse brain
24. Comparison of structural and stereoisomers of apomorphine on stereotyped behavior of the rat
25. Dopamine D2 receptor binding sites for agonists. A tetrahedral model
26. Radiosynthesis and in vitro evaluation of 2-(N-alkyl-N-1-11C-propyl)amino-5-hydroxytetralin analogs as high affinity agonists for dopamine D-2 receptors
27. In vivo binding of N-n-propylnorapomorphine in the rat brain: Regional localization, quantification in striatum and lack of correlation with dopamine metabolism
28. MRI-PET registration with automated algorithm
29. Electrophysiological, biochemical and behavioral assessment of dopamine autoreceptor activation by a series of dopamine agonists
30. Synthesis and in vivo distribution in the rat of several fluorine-18 labeled 5-hydroxy-2-aminotetralin derivatives
31. Synthesis and in vivo distribution in the rat of a dopamine agonist: N-([11C]methyl)norampomorphine
32. Synthesis and in vivo distribution in the rat of several fluorine-18 labeled N-fluoroalkylaporphines